• Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 424.48 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.86
▼ -0.06 (-2.05%)

This chart shows the closing price for NOVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NOVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NOVN

Analyst Price Target is $15.00
▲ +424.48% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Novan in the last 3 months. The average price target is $15.00, with a high forecast of $17.00 and a low forecast of $12.00. The average price target represents a 424.48% upside from the last price of $2.86.

This chart shows the closing price for NOVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Novan. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2022HC WainwrightLower TargetBuy$24.00 ➝ $17.00Low
7/19/2022OppenheimerInitiated CoverageOutperform$12.00Low
3/15/2022HC WainwrightReiterated RatingBuy$24.00High
10/19/2021Brookline Capital ManagementReiterated RatingBuy$16.00Medium
9/21/2021Cantor FitzgeraldReiterated RatingBuyLow
7/9/2021Cantor FitzgeraldInitiated CoverageOverweightHigh
5/4/2021HC WainwrightBoost TargetBuy$1.50 ➝ $2.00High
4/22/2021Roth CapitalInitiated CoverageBuy$3.00High
5/26/2020HC WainwrightReiterated RatingBuy$1.50Low
1/6/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $1.50N/A
1/5/2020Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$0.50N/A
3/29/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
12/10/2018HC WainwrightSet TargetBuy$6.00High
11/16/2018HC WainwrightSet TargetBuy$8.00Low
11/6/2018HC WainwrightReiterated RatingBuy$8.00Medium
10/26/2018HC WainwrightInitiated CoverageBuy$8.00Low
7/20/2018Piper Jaffray CompaniesReiterated RatingBuy$6.00High
5/21/2018JMP SecuritiesSet TargetBuy$14.00Low
9/25/2017WedbushReiterated RatingNeutral$6.00High
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Novan logo
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $2.86
Low: $2.84
High: $2.99

50 Day Range

MA: $2.60
Low: $2.29
High: $3.03

52 Week Range

Now: $2.86
Low: $2.15
High: $10.40

Volume

131,227 shs

Average Volume

225,361 shs

Market Capitalization

$60.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Novan?

The following equities research analysts have issued reports on Novan in the last year: Brookline Capital Management, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for NOVN.

What is the current price target for Novan?

3 Wall Street analysts have set twelve-month price targets for Novan in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 424.5%. HC Wainwright has the highest price target set, predicting NOVN will reach $17.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $12.00 for Novan in the next year.
View the latest price targets for NOVN.

What is the current consensus analyst rating for Novan?

Novan currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NOVN will outperform the market and that investors should add to their positions of Novan.
View the latest ratings for NOVN.

What other companies compete with Novan?

How do I contact Novan's investor relations team?

Novan's physical mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company's listed phone number is (919) 485-8080 and its investor relations email address is [email protected] The official website for Novan is www.novan.com. Learn More about contacing Novan investor relations.